The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.
- Authors
- Bloom, Joseph; Hinrichs, Anthony L; Wang, Jen C; von Weymarn, Linda B; Kharasch, Evan D; Bierut, Laura J; Goate, Alison; Murphy, Sharon E
- Year
- 2011
- Journal
- Pharmacogenetics and genomics
- PMID
- 21597399
- DOI
- 10.1097/FPC.0b013e328346e8c0
- PMCID
- PMC3116045
OBJECTIVE: To study the association between cytochrome P450 2A6 (CYP2A6) genotype and metabolism of nicotine to cotinine, identify functional polymorphisms, and develop a predictive genetic model of nicotine metabolism. METHODS: The conversion of deuterated (D2)-nicotine to D2-cotinine was quantified in 189 European-Americans and the contribution of CYP2A6 genotype to variability in first-pass nicotine metabolism was assessed. Specifically, (i) single time point measures of D2-cotinine/(D2-cotinine+D2-nicotine) after oral administration were used as a metric of CYP2A6 activity; (ii) the impact of CYP2A6 haplotype was treated as acting multiplicatively; (iii) parameter estimates were calculated for all haplotypes in the subject pool, defined by a set of polymorphisms previously reported to affect function, including gene copy number; and (iv) a minimum number of predictive polymorphisms were justified to be included in the model based on statistical evidence of differences between haplotypes. RESULTS: The final model includes seven polymorphisms and fits the phenotype, 30-min after D2-nicotine oral administration, with R=0.719. The predictive power of the model is robust: parameter estimates calculated in men (n=89) predict the phenotype in women (n=100) with R=0.758 and vice versa with R=0.617; estimates calculated in current smokers (n=102) predict the phenotype in former-smokers (n=86) with R=0.690 and vice versa with R=0.703. Comparisons of haplotypes also demonstrate that CYP2A6*12 is a loss-of-function allele indistinguishable from CYP2A6*4 and CYP2A6*2 and that the CYP2A6*1B 5'-untranslated region conversion has negligible impact on metabolism. After controlling for CYP2A6 genotype, modest associations were found between increased metabolism and both female sex (P=4.8Γ10) and current smoking (P=0.02). CONCLUSION: Among European-Americans, seven polymorphisms in the CYP2A6 gene explain the majority of variability in the metabolism of nicotine to cotinine after oral administration. Parameters determined from this in-vivo experiment can be used to predict nicotine metabolism based on CYP2A6 genotype.
CYP2A6 diplotype/ phenotype association. Time 1 (t1) =30 min. The boxplot provides a summary of the data distribution. The box represents the interquartile range, which includes 50% of values. The line across the box indicates the median. The whisker lines extend to the highest and lowest values that are within 1.5x the interquartile range. Further outliers are marked with circles.
CYP2A6 diplotype/ phenotype association among normal metabolizer alleles, CYP2A6*1B,*1D,*1H, and *14. Time 1 (t1) =30 min. The boxplot provides a summary of the data distribution. The box represents the interquartile range, which includes 50% of values. The line across the box indicates the median. The whisker lines extend to the highest and lowest values that are within 1.5x the interquartile range. Further outliers are marked with circles. N = CYP2A6 normal metabolizer haplotypes (*1B,*1D,*1H,*14); *1A = CYP2A6*1A(51A);*9 = CYP2A6*9; L = CYP2A6 putative loss-of-function haplotypes (*2, *4, *12). The N/N (n=95) group is significantly greater than the N/*1A (n=33, p=0.0001), N/*9 (n=20, p=6.1Γ10β5), and *1A/*1A (n=8, p=0.008) groups. The L/N (n=17) group is significantly greater than the L/*1A group (n=4, p=0.0002).
The Distribution of log(D2cotinine/D2nicotine)(A) and D2cotinine/(D2cotinine+D2nicotine) (B) measured at time1 (t1, 30 minutes) among 189 European American subjects displayed as a cumulative histogram color-coded by diplotype class. White = normal/normal, Yellow = normal/intermediate, Green = intermediate/intermediate, Blue = normal/null, Purple = intermediate/null, Red = null/null. Normal haplotypes are *1A(51G),*1B, *1D,*1H and *14. Intermediate haplotypes are *1A(51A) and *9. Null haplotypes are *1D-Y351H, *2, *4 and *12. Genotype is not further differentiated.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Dose-response relationship between cotinine levels and female reproductive lifespan. | Liao J et al. | β | 2026 | β |
| Genetic and Environmental Factors of Nicotine Addiction: Examination of Multiple Substance Addictions. | Albayrak M et al. | β | 2026 | β |
| Time from waking to first cigarette, genetic susceptibility, and the risk of COPD: A Prospective cohort study from UK Biobank. | Qiqi L et al. | β | 2026 | β |
| CHRNA5-A3-B4, CYP2A6, and DBH Genetic Associations With Smoking Cessation Throughout Adulthood Within Two Longitudinal Studies of Women. | Jones SK et al. | β | 2025 | β |
| Fine-mapping the CYP2A6 regional association with nicotine metabolism among African American smokers. | Pouget JG et al. | β | 2025 | β |
| CYP2A6 associates with respiratory disease risk and younger age of diagnosis: a phenome-wide association Mendelian Randomization study. | Giratallah H et al. | β | 2024 | β |
| Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample. | Cinciripini PM et al. | β | 2024 | β |
| PharmVar GeneFocus: CYP2A6. | Langlois AWR et al. | β | 2024 | β |
| G-quadruplex forming sequences in the genes coding for cytochrome P450 enzymes and their potential roles in drug metabolism. | Saad M et al. | β | 2023 | β |
| Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers. | Perez-Paramo YX et al. | β | 2023 | β |
| Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes. | Langlois AWR et al. | β | 2022 | β |
| Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review. | Jones SK et al. | β | 2022 | β |
| Multiethnic Prediction of Nicotine Biomarkers and Association With Nicotine Dependence. | Bergen AW et al. | β | 2021 | β |
| Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. | Perez-Paramo YX et al. | β | 2021 | β |
| Transferability of Ancestry-Specific and Cross-Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations. | El-Boraie A et al. | β | 2021 | β |
| A prospective study of the association between rate of nicotine metabolism and alcohol use in tobacco users in the United States. | Roberts W et al. | β | 2020 | β |
| Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. | El-Boraie A et al. | β | 2020 | β |
| Genetic variants in CYP2A6 and UGT1A9 genes associated with urinary nicotine metabolites in young Mexican smokers. | Borrego-Soto G et al. | β | 2020 | β |
| Multiethnic Prediction of Nicotine Biomarkers and Association with Nicotine Dependence | Bergen AW et al. | β | 2020 | β |
| The Novel CYP2A6 Inhibitor, DLCI-1, Decreases Nicotine Self-Administration in Mice. | Chen YC et al. | β | 2020 | β |
| Cancer Hazard Identification Integrating Human Variability: The Case of Coumarin. | Hsieh CJ et al. | β | 2019 | β |
| Mouse strain-specific acute respiratory effects of nicotine unrelated to nicotine metabolism. | Bloom AJ | β | 2019 | β |
| Neurogenetic determinants and mechanisms of addiction to nicotine and smoked tobacco. | Sharp BM et al. | β | 2019 | β |
| Pregnancy-Induced Increases in the Nicotine Metabolite Ratio: Examining Changes During Antepartum and Postpartum. | Arger CA et al. | β | 2019 | β |
| Biosignature Discovery for Substance Use Disorders Using Statistical Learning. | Baurley JW et al. | β | 2018 | β |
| CYP2A6 metabolism in the development of smoking behaviors in young adults. | Olfson E et al. | β | 2018 | β |
| Cytochrome P450 in Pharmacogenetics: An Update. | Tornio A et al. | β | 2018 | β |
| Genetic polymorphisms of the drug-metabolizing enzyme cytochrome P450 2A6 in a Tibetan Chinese population. | Xia R et al. | β | 2018 | β |
| Longitudinal Influence of Pregnancy on Nicotine Metabolic Pathways. | Taghavi T et al. | β | 2018 | β |
| Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain. | Teitelbaum AM et al. | β | 2018 | β |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | β | 2018 | β |
| The effect of <i>CYP1A2</i> gene polymorphism on the metabolism of theophylline. | Xiong S et al. | β | 2018 | β |
| The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. | Saccone NL et al. | β | 2018 | β |
| Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors. | Chen LS et al. | β | 2018 | β |
| CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study. | Yuan JM et al. | β | 2017 | β |
| Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. | LΓ³pez-Flores LA et al. | β | 2017 | β |
| Genetic polymorphisms in CYP2A6 are associated with a risk of cigarette smoking and predispose to smoking at younger ages. | PΓ©rez-Rubio G et al. | β | 2017 | β |
| Genetic susceptibility variants for lung cancer: replication study and assessment as expression quantitative trait loci. | Pintarelli G et al. | β | 2017 | β |
| Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6. | Murphy SE | β | 2017 | β |
| CYP2A6 Effects on Subjective Reactions to Initial Smoking Attempt. | Cannon DS et al. | β | 2016 | β |
| CYP2A6 Longitudinal Effects in Young Smokers. | Cannon DS et al. | β | 2016 | β |
| Genetic determinants of CYP2A6 activity across racial/ethnic groups with different risks of lung cancer and effect on their smoking intensity. | Park SL et al. | β | 2016 | β |
| Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study. | Yuan JM et al. | β | 2016 | β |
| Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries. | Baurley JW et al. | β | 2016 | β |
| Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. | Patel YM et al. | β | 2016 | β |
| Smokescreen: a targeted genotyping array for addiction research. | Baurley JW et al. | β | 2016 | β |
| To quit or not: Vulnerability of women to smoking tobacco. | Park SJ et al. | β | 2016 | β |
| Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. | Mamoun M et al. | β | 2015 | β |
| Does ethnic ancestry play a role in smoking? | De Souza ES et al. | β | 2015 | β |
| Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. | Bergen AW et al. | β | 2015 | β |
| The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. | Patel YM et al. | β | 2015 | β |
| A pilot study of concurrent lead and cotinine screening for childhood tobacco smoke exposure: effect on parental smoking. | Joseph A et al. | β | 2014 | β |
| Beyond cigarettes per day. A genome-wide association study of the biomarker carbon monoxide. | Bloom AJ et al. | β | 2014 | β |
| Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability. | Fowler CD et al. | β | 2014 | β |
| Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). | Chen LS et al. | β | 2014 | β |
| Prenatal tobacco exposure and cotinine in newborn dried blood spots. | Spector LG et al. | β | 2014 | β |
| Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. | Bloom AJ et al. | β | 2014 | β |
| A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele. | Bloom AJ et al. | β | 2013 | β |
| Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. | Djordjevic N et al. | β | 2013 | β |
| Cotinine and trans 3'-hydroxycotinine in dried blood spots as biomarkers of tobacco exposure and nicotine metabolism. | Murphy SE et al. | β | 2013 | β |
| CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes. | Bloom AJ et al. | β | 2013 | β |
| Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption. | Bloom AJ et al. | β | 2013 | β |
| The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans. | Bloom AJ et al. | β | 2013 | β |
| A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. | Cho MH et al. | β | 2012 | β |
| CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine Ξ5'(1')iminium ion. | von Weymarn LB et al. | β | 2012 | β |
| Effects of tobacco smoking and nicotine on cancer treatment. | Petros WP et al. | β | 2012 | β |
| Intra- and inter-individual variability in urinary nicotine excretion and plasma cotinine in adult cigarette smokers. | Liang Q et al. | β | 2012 | β |
| Pathway analysis of smoking quantity in multiple GWAS identifies cholinergic and sensory pathways. | Harari O et al. | β | 2012 | β |
| Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. | Gold AB et al. | β | 2012 | β |
| PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. | McDonagh EM et al. | β | 2012 | β |
| Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer. | Zienolddiny S et al. | β | 2012 | β |
| The genetics of substance dependence. | Wang JC et al. | β | 2012 | β |
| Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. | Bloom AJ et al. | β | 2012 | β |
| Chronic nicotine consumption does not influence 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis. | Murphy SE et al. | β | 2011 | β |
| The Role of the Habenula in Nicotine Addiction. | Baldwin PR et al. | β | 2011 | β |